Tiziana Life Sciences PLC(TLSA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

TLSA Tiziana Life Sciences PLC

Market Closed 09-04 16:00:00 EDT

1.02

+0.05

+4.67%

盘后1.01

-0.01-0.98%

19:30 EDT

High1.06	Low0.9507	Vol573.92K
Open0.9720	D1 Closing0.9745	Amplitude11.22%
Mkt Cap129.54M	Tradable Cap66.18M	Total Shares127.00M
T/O576.92K	T/O Rate0.88%	Tradable Shares64.88M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"TLSA","market":"US","secType":"STK","nameCN":"Tiziana Life Sciences PLC","latestPrice":1.02,"timestamp":1788552000000,"preClose":0.9745,"halted":0,"volume":573921,"hourTrading":{"tag":"盘后","latestPrice":1.01,"preClose":1.02,"latestTime":"19:30 EDT","volume":3456,"amount":3525.7,"timestamp":1788564602694,"change":-0.01,"changeRate":-0.009804,"amplitude":0.019608},"delay":0,"changeRate":0.04669061056952282,"floatShares":64882543,"shares":127000000,"eps":-0.155821,"marketStatus":"Market Closed","change":0.0455,"latestTime":"09-04 16:00:00 EDT","open":0.972,"high":1.06,"low":0.9507,"amount":576922.3198695,"amplitude":0.11216,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.155821,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1788854400000},"marketStatusCode":7,"adr":0,"adrRate":2,"listingDate":1542690000000,"exchange":"NASDAQ","adjPreClose":0.9745,"preHourTrading":{"tag":"盘前","latestPrice":1.01,"preClose":0.9745,"latestTime":"09:20 EDT","volume":4060,"amount":4194.066478,"timestamp":1788528033188,"change":0.0355,"changeRate":0.036429,"amplitude":0.092355},"postHourTrading":{"tag":"盘后","latestPrice":1.01,"preClose":1.02,"latestTime":"19:30 EDT","volume":3456,"amount":3525.7,"timestamp":1788564602694,"change":-0.01,"changeRate":-0.009804,"amplitude":0.019608},"volumeRatio":1.1397248796578165,"impliedVol":1.1411,"impliedVolPercentile":0.8175},"requestUrl":"/m/hq/s/TLSA","defaultTab":"news","newsList":[{"id":"2664299875","title":"Tiziana Life Sciences Initiated at Buy by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2664299875","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664299875?lang=en_us&edition=fundamental","pubTime":"2026-09-03 18:18","pubTimestamp":1788430680,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TLSA/analyst-ratings","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLSA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664873409","title":"Tiziana Life Sciences Ltd : Btig Initiates Coverage with Buy Rating; Price Target $7","url":"https://stock-news.laohu8.com/highlight/detail?id=2664873409","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664873409?lang=en_us&edition=fundamental","pubTime":"2026-09-03 17:51","pubTimestamp":1788429094,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nFWN44V0IG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLSA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661323273","title":"Tiziana Life Sciences Launches Phase 2a Banyan Trial of Intranasal Foralumab in ALS","url":"https://stock-news.laohu8.com/highlight/detail?id=2661323273","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661323273?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:00","pubTimestamp":1787569233,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences launches Phase 2a BANYAN trial of intranasal foralumab in ALSTiziana Life Sciences announced a Phase 2a BANYAN trial of intranasal foralumab in ALS within the Healey ALS MyMatch ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nNDLsJD9F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","SG9999014039.USD","IE00BQXX3C00.GBP","BCDF","SG9999014005.SGD","IE00BQXX3D17.EUR","LU0314104364.USD","NDAQ","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","LU2210149790.SGD","TLSA","IE00BGHQF748.EUR","SG9999014013.SGD","IE00BKPKM429.USD","IE00BQXX3F31.USD","BK4585","IE00B64PRP62.GBP","IE00BN0W2W23.USD","LU2210150020.SGD","BK4112","SG9999014021.USD","IE00BN0W2T93.GBP","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661273805","title":"Tiziana Life Sciences Announces Poster Presentation on Phase 2a Banyan Clinical Trial of Intranasal Foralumab at ALS Nexus 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2661273805","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661273805?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:00","pubTimestamp":1787569201,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nTUA8XKWHH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLSA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657638932","title":"Tiziana Life Sciences CEO Elrifi Buys USD 321,423 in Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2657638932","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657638932?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:05","pubTimestamp":1786014311,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences CEO Elrifi buys USD 321,423 in sharesTiziana Life Sciences CEO Ivor Elrifi bought 321,423 common shares on Nasdaq at $1 per share.Holding increased to 4,793,684 common shares.Dis","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL8MRBwz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Tiziana Life Sciences CEO Elrifi Buys USD 321,423 in Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLSA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657638625","title":"Press Release: Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2657638625","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657638625?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:00","pubTimestamp":1786014000,"startTime":"0","endTime":"0","summary":"BOSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (\"Tiziana\" or the \"Company\"), a biotechnology company developing breakthrough immunomodulation therapies with its l","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNGE","LU1430594728.SGD","LU1043141396.HKD","LU2506951875.HKD","LU0823417737.USD","LU0823417653.USD","HERO","LU1585245621.USD","BK4577","LU1043141123.HKD","TLSA","LU2506952170.USD","LU2506952097.USD","LU2247934214.USD","BK4588","LU0006061336.USD","BK4585","LU0950375773.USD","BK4085","LU0426417589.USD","NERD","LU0426412945.USD","LU0994945656.USD","EA","BK4533","LU1121112475.USD","LU2506951958.HKD","BK4532","BK4139","LU1280957306.USD","ESPO","LU0640476718.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657573647","title":"Tiziana CEO Ivor Elrifi Acquires 667,000 Common Shares for $667,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2657573647","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657573647?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:32","pubTimestamp":1785961946,"startTime":"0","endTime":"0","summary":"Tiziana CEO Ivor Elrifi acquires 667,000 common shares for $667,000Tiziana Life Sciences CEO Ivor Elrifi reported an indirect purchase of 667,000 common shares at USD 1 per share.Indirect holdings hel","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nNDL81yhT5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Tiziana CEO Ivor Elrifi Acquires 667,000 Common Shares for $667,000","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLSA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656514530","title":"Tiziana Life Sciences CEO Ivor Elrifi Lifts Stake to 4,472,261 Shares After Buying 667,000 at $1 Apiece","url":"https://stock-news.laohu8.com/highlight/detail?id=2656514530","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656514530?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:00","pubTimestamp":1785841217,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences CEO Ivor Elrifi lifts stake to 4,472,261 shares after buying 667,000 at $1 apieceCEO Ivor Elrifi bought 667,000 Tiziana Life Sciences common shares on Nasdaq at $1 per share.The ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nNDL5td0S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","SG9999014039.USD","BCDF","TLSA","LU2210149790.SGD","IE00BN0W2W23.USD","SG9999014005.SGD","SG9999014013.SGD","LU0314104364.USD","BK4139","BK4112","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","NDAQ","LU2210150020.SGD","IE00B3QW5Z07.USD","BK4588","LU2095319765.USD","IE00BKPKM429.USD","SG9999014021.USD","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656908530","title":"Press Release: Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2656908530","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656908530?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:00","pubTimestamp":1785841200,"startTime":"0","endTime":"0","summary":"BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (\"Tiziana\" or the \"Company\"), a biotechnology company developing breakthrough immunomodulation therapies with its l","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NERD","LU2506952170.USD","BK4588","LU0640476718.USD","LU0950375773.USD","LU0823417653.USD","BK4139","LU2247934214.USD","BK4585","HERO","LU0426417589.USD","TLSA","BK4085","LU1585245621.USD","LU1280957306.USD","BNGE","LU0006061336.USD","LU1043141123.HKD","EA","LU1121112475.USD","LU0426412945.USD","BK4533","ESPO","LU2506951958.HKD","LU1430594728.SGD","BK4532","LU0994945656.USD","BK4577","LU1043141396.HKD","LU2506952097.USD","LU2506951875.HKD","LU0823417737.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655368159","title":"Tiziana Reports up to 34% Drop in Brain Inflammation in Third MSA Patient on Intranasal Foralumab in Phase 2 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2655368159","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655368159?lang=en_us&edition=fundamental","pubTime":"2026-07-31 19:04","pubTimestamp":1785495890,"startTime":"0","endTime":"0","summary":"Tiziana reports up to 34% drop in brain inflammation in third MSA patient on intranasal foralumab in Phase 2 trialTiziana Life Sciences reported Phase 2 PET imaging results from a third multiple syste","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nNDLNB35p:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","LU0314104364.USD","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","LU2095319765.USD","SG9999014021.USD","IE00BKPKM429.USD","LU2210150020.SGD","BK4588","LU2210149790.SGD","SG9999014013.SGD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","SG9999014005.SGD","IE00B3QW5Z07.USD","SG9999014039.USD","BCDF","BK4585","BK4112","TLSA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655686633","title":"Tiziana Life Sciences - Third MSA Patient Shows up to 34% Reduction in SUV and 26% in Suvr in Brain Regions","url":"https://stock-news.laohu8.com/highlight/detail?id=2655686633","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655686633?lang=en_us&edition=fundamental","pubTime":"2026-07-31 19:01","pubTimestamp":1785495688,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nFWN43X20I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TLSA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655368661","title":"Tiziana Life Sciences - to Continue Evaluating Intranasal Foralumab in Additional MSA Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2655368661","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655368661?lang=en_us&edition=fundamental","pubTime":"2026-07-31 19:01","pubTimestamp":1785495688,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nFWN43X20I:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TLSA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653927775","title":"Tiziana Life Sciences CEO Ivor Elrifi Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2653927775","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653927775?lang=en_us&edition=fundamental","pubTime":"2026-07-24 04:21","pubTimestamp":1784838070,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences CEO Ivor Elrifi files initial beneficial ownership statementTiziana Life Sciences CEO Ivor Elrifi reported 3,805,261 common shares, with 3,150,000 restricted stock units exercisa","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260723:nNDL1DqJkY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLSA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653754903","title":"Tiziana Life Sciences Chairman Cerrone Raises Stake to 34.93% After Buying 42,357 Shares at $0.99","url":"https://stock-news.laohu8.com/highlight/detail?id=2653754903","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653754903?lang=en_us&edition=fundamental","pubTime":"2026-07-22 19:00","pubTimestamp":1784718043,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences chairman Cerrone raises stake to 34.93% after buying 42,357 shares at $0.99Executive Chairman Gabriele Cerrone bought 42,357 common shares at $0.99, lifting his stake to 44,814,5","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nNDL2SDbXw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","BK4112","IE00BN0W2T93.GBP","LU2210150020.SGD","IE00B3QW5Z07.USD","SG9999014021.USD","LU2095319765.USD","IE00BN0W2V16.EUR","BK4139","SG9999014039.USD","NDAQ","BCDF","BK4585","IE00BGHQF748.EUR","TLSA","IE00BKPKM429.USD","LU0314104364.USD","BK4588","IE00BN0W2W23.USD","LU2210149790.SGD","SG9999014005.SGD","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646737874","title":"Tiziana Life Sciences Completes First Dosing in Phase 2 Inform-ms Trial of Intranasal Foralumab in Secondary Progressive MS","url":"https://stock-news.laohu8.com/highlight/detail?id=2646737874","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646737874?lang=en_us&edition=fundamental","pubTime":"2026-06-25 19:00","pubTimestamp":1782385241,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences completes first dosing in Phase 2 INFORM-MS trial of intranasal foralumab in secondary progressive MSTiziana Life Sciences dosed the last patient in its Phase 2a INFORM-MS trial ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nNDLccXs4k:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","IE00B64PRP62.GBP","SG9999014005.SGD","SG9999014021.USD","LU2095319765.USD","BK4139","BK4112","IE00BGHQF748.EUR","NDAQ","SG9999014013.SGD","IE00BKPKM429.USD","IE00B3QW5Z07.USD","BK4585","LU2210149790.SGD","BK4588","TLSA","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","SG9999014039.USD","IE00BN0W2V16.EUR","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646874779","title":"Tiziana Announces Last Patient Successfully Dosed in Its Phase 2 Inform-ms Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2646874779","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646874779?lang=en_us&edition=fundamental","pubTime":"2026-06-25 19:00","pubTimestamp":1782385200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nTUA76VG3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLSA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646387470","title":"Tiziana Life Sciences - Topline Data from Inform-ms Trial Expected Late Q3 or Early Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2646387470","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646387470?lang=en_us&edition=fundamental","pubTime":"2026-06-25 19:00","pubTimestamp":1782385200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nTUA76VG3:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLSA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643087182","title":"Tiziana Life Sciences Executive Chairman Gabriele Cerrone Increases Holdings","url":"https://stock-news.laohu8.com/highlight/detail?id=2643087182","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643087182?lang=en_us&edition=fundamental","pubTime":"2026-06-15 19:55","pubTimestamp":1781524514,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences  Executive Chairman and founder, Gabriele Cerrone, has increased his holdings with the purchase of 15,000 shares at $1.11 each, the company said Monday.The purchase, through Panetta Partners, brings his total holding to 44.8 million shares, or 34.9% of issued share capital.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","TLSA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637881342","title":"Tiziana Life Sciences’ COO and CFO Keeren Shah files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2637881342","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637881342?lang=en_us&edition=fundamental","pubTime":"2026-05-23 04:56","pubTimestamp":1779483365,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences Chief Operating & Financial Officer Keeren Shah filed an initial beneficial ownership statement reporting 2,500 shares of common stock.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tiziana Life Sciences Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 22, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nNDL2hx8Pw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLSA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637330249","title":"Tiziana Life Sciences Completes Patient Enrollment for Phase 2a Multiple Sclerosis Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2637330249","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637330249?lang=en_us&edition=fundamental","pubTime":"2026-05-21 23:39","pubTimestamp":1779377993,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences  has completed patient enrollment for the phase 2a clinical trial evaluating intranasal foralumab in patients with non-active secondary progressive multiple sclerosis.The trial enrolled 48 patients in the US who will receive one of two doses of intranasal foralumab or placebo over a 12-week period, to be followed by a six-month open label extension phase, the company said.Topline data from the trial is expected in late Q3, Tiziana added.Price: 1.73, Change: +0.12, Percent Change: +7.45","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLSA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tizianalifesciences.com","stockEarnings":[{"period":"1week","weight":0.0099},{"period":"1month","weight":0.0303},{"period":"3month","weight":-0.1774},{"period":"6month","weight":-0.2662},{"period":"1year","weight":-0.3544},{"period":"ytd","weight":-0.3154}],"compareEarnings":[{"period":"1week","weight":0.0011},{"period":"1month","weight":0.0005},{"period":"3month","weight":0.0443},{"period":"6month","weight":0.1455},{"period":"1year","weight":0.1865},{"period":"ytd","weight":0.1294}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-  receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.","yearOnYearQuotes":[{"month":1,"riseRate":0.375,"avgChangeRate":0.062066},{"month":2,"riseRate":0.125,"avgChangeRate":0.000048},{"month":3,"riseRate":0.375,"avgChangeRate":0.130911},{"month":4,"riseRate":0.625,"avgChangeRate":0.144279},{"month":5,"riseRate":0.5,"avgChangeRate":0.187138},{"month":6,"riseRate":0.375,"avgChangeRate":-0.011823},{"month":7,"riseRate":0.375,"avgChangeRate":0.26158},{"month":8,"riseRate":0.25,"avgChangeRate":-0.130353},{"month":9,"riseRate":0.375,"avgChangeRate":-0.01003},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.076885},{"month":11,"riseRate":0,"avgChangeRate":-0.127748},{"month":12,"riseRate":0,"avgChangeRate":-0.132657}],"exchange":"NASDAQ","name":"Tiziana Life Sciences PLC","nameEN":"Tiziana Life Sciences PLC","securityTypeName":"DR","adrRate":"1:2"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Tiziana Life Sciences PLC(TLSA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Tiziana Life Sciences PLC(TLSA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Tiziana Life Sciences PLC,TLSA,Tiziana Life Sciences PLC股票,Tiziana Life Sciences PLC股票老虎,Tiziana Life Sciences PLC股票老虎国际,Tiziana Life Sciences PLC行情,Tiziana Life Sciences PLC股票行情,Tiziana Life Sciences PLC股价,Tiziana Life Sciences PLC股市,Tiziana Life Sciences PLC股票价格,Tiziana Life Sciences PLC股票交易,Tiziana Life Sciences PLC股票购买,Tiziana Life Sciences PLC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Tiziana Life Sciences PLC(TLSA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Tiziana Life Sciences PLC(TLSA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}